HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stada’s ViruProtect Could Prevent COVID Infection, In Vitro Study Shows

Executive Summary

A recent in vitro study shows that Enzymatica's ColdZyme throat spray – the basis for Stada's ViruProtect in Belgium and Austria – could offer a protective barrier against harmful viruses such as SARS-CoV-2.

You may also be interested in...



Don’t Let COVID Bring You Down: New German Immunity Boosters From Stada, Pascoe And More

New German wellness launches: Immunity boosting food supplements from Stada, Pascoe, Dr Scheffler, Queisser and Infecto.

Stada's Nature’s Aid Submits CBD Novel Food Application

HBW Insight speaks exclusively to Chris Morrey, CEO of Stada's UK Nature's Aid subsidiary, about the company's experiments with CBD and its recently submitted EU novel food application. 

Stada’s Goldschmidt Looks To Take Consumer Health Global

Stada CEO Peter Goldschmidt tells HBW Insight about his ambition to enter the US consumer health market as part of a push to take the business global. 

Related Content

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel